Cordycepin Modulates Microglial M2 Polarization Coupled with Mitochondrial Metabolic Reprogramming by Targeting HKII and PDK2
Authors:
Open Access
- 18 June 2024
- journal article
- research article
- Published by Wiley in Advanced Science
- Vol. 11 (31) , e2304687
Abstract
The microenvironment mediated by the microglia (MG) M1/M2 phenotypic switch plays a decisive role in the neuronal fate and cognitive function of Alzheimer's disease (AD). However, the impact of metabolic reprogramming on microglial polarization and its underlying mechanism remains elusive. This study reveals that cordycepin improved cognitive function and memory in APP/PS1 mice, as well as attenuated neuronal damage by triggering MG‐M2 polarization and metabolic reprogramming characterized by increased OXPHOS and glycolysis, rather than directly protecting neurons. Simultaneously, cordycepin partially alleviates mitochondrial damage in microglia induced by inhibitors of OXPHOS and glycolysis, further promoting MG‐M2 transformation and increasing neuronal survival. Through confirmation of cordycepin distribution in the microglial mitochondria via mitochondrial isolation followed by HPLC‐MS/MS techniques, HKII and PDK2 are further identified as potential targets of cordycepin. By investigating the effects of HKII and PDK2 inhibitors, the mechanism through which cordycepin targeted HKII to elevate ECAR levels in the glycolysis pathway while targeting PDK2 to enhance OCR levels in PDH‐mediated OXPHOS pathway, thereby inducing MG‐M2 polarization, promoting neuronal survival and exerting an anti‐AD role is elucidated.Keywords
Funding Information
- Major Basic Research Project of the Natural Science Foundation of the Jiangsu Higher Education Institutions (LJKZ0775)
- Key Research and Development Program of Liaoning Province (2018225089)
- Doctoral Start-up Foundation of Liaoning Province (2019‐BS‐289)
- National Natural Science Foundation of China (81901309)
This publication has 50 references indexed in Scilit:
- Nanomaterials as Microglia Modulators in the Treatment of Central Nervous System DisordersAdvanced Healthcare Materials, 2024
- Epigallocatechin‐3‐Gallate Attenuates Microglial Inflammation and Neurotoxicity by Suppressing the Activation of Canonical and Noncanonical Inflammasome via TLR4/NF‐κB PathwayMolecular Nutrition & Food Research, 2019
- Imbalance of Microglial TLR4/TREM2 in LPS-Treated APP/PS1 Transgenic Mice: A Potential Link Between Alzheimer’s Disease and Systemic InflammationNeurochemical Research, 2019
- Melatonin as a mitochondria-targeted antioxidant: one of evolution’s best ideasCellular and Molecular Life Sciences, 2017
- Involvement of the Warburg effect in non‐tumor diseases processesJournal of Cellular Physiology, 2017
- (−)-Epigallocatechin-3-Gallate Ameliorates Learning and Memory Deficits by Adjusting the Balance of TrkA/p75NTR Signaling in APP/PS1 Transgenic MiceMolecular Neurobiology, 2013
- Cannabinoid Effects on β Amyloid Fibril and Aggregate Formation, Neuronal and Microglial-Activated Neurotoxicity In VitroCellular and Molecular Neurobiology, 2013
- Brain glucose metabolism in the early and specific diagnosis of Alzheimer?s diseaseEuropean Journal of Nuclear Medicine and Molecular Imaging, 2005
- Crystal structures of mutant monomeric hexokinase I reveal multiple ADP binding sites and conformational changes relevant to allosteric regulation 1 1Edited by P. E. WrightJournal of Molecular Biology, 2000
- Altered hexokinase activity in skin cultured fibroblasts and leukocytes from Alzheimer's disease patientsNeuroscience Letters, 1990